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   Multidrug and toxin extrusion 1 (MATE1/SLC47A1) is expressed in the brush-border 
membrane of renal proximal tubules and mediates the efflux of cationic drugs.  In the 
present study, the role of MATE1 in the nephrotoxicity of cisplatin was investigated in vivo 
and in vitro.  Cisplatin (15 mg/kg) was administered intraperitoneally to wild-type 
(Mate1(+/+)) and Mate1 knockout (Mate1(-/-)) mice.  Lifespan was significantly shorter in 
Mate1(-/-) mice than Mate1(+/+) mice.  Three days after the administration of cisplatin, 
plasma creatinine and blood urea nitrogen (BUN) levels were increased in both Mate1(+/+) 
and Mate1(-/-) mice compared with vehicle-treated controls, and creatinine clearance was 
decreased.  Moreover, a significant rise in creatinine and BUN levels was observed in 
cisplatin-treated Mate1(-/-) mice in comparison to Mate1(+/+) mice.  A pharmacokinetic 
analysis revealed the plasma concentration and renal accumulation of cisplatin to be higher in 
Mate1(-/-) mice than Mate1(+/+) mice 1 h after a single intravenous administration of 
cisplatin (0.5 mg/kg).  Furthermore, the combination of a selective MATE inhibitor, 
pyrimethamine, with cisplatin also elevated creatinine and BUN levels compared to cisplatin 
alone.  In experiments in vitro, the cellular uptake of cisplatin was stimulated by the 
expression of mouse MATE1 as well as organic cation transporters OCT1 and OCT2.  In 
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1. Introduction 
The platinum-based anticancer drug cis-diamminedichloroplatinum II (cisplatin) has been 
used clinically for over 30 years, and continues to play an essential role in chemotherapy 
against malignant solid tumors of the lung, bladder, colon, testis and brain.  However, severe 
nephrotoxicity limits its application.  An increase in the serum creatinine concentration has 
been reported in 41% of patients treated with a high dose of cisplatin [1].  Experiments with 
rats revealed that renal damage from cisplatin occurred primarily in proximal tubules [2].  In 
addition, a pharmacokinetic study showed that concentration of cisplatin was higher in renal 
tissue than in other tissues or plasma [3].  These reports suggested transporters expressed in 
renal proximal tubular epithelial cells to be involved in the nephrotoxicity of cisplatin.   
Human organic cation transporter 2 (hOCT2/SLC22A2) is expressed in the basolateral 
membrane of proximal tubules and mediates the accumulation of various cationic drugs in the 
kidney [4, 5].  Human multidrug and toxin extrusion 1 (hMATE1/SLC47A1) and 
hMATE2-K (SLC47A2) are expressed in the brush-border membrane of renal proximal 
tubules [6, 7], and transport organic cations with an oppositely directed H+ gradient as a 
driving force [8].  A species difference in the tissue distribution of OCT and MATE is 
known.  In mice, not only OCT2 but also OCT1 is expressed in the kidney [9, 10].  Mouse 
(m) MATE1 is expressed in renal proximal tubules [6].  MATE2-K is not found in mice.  
Recently, we generated Mate1 knockout (Mate1(-/-)) mice, and showed that MATE1 plays a 
predominant role in the renal tubular secretion of metformin [11].  OCT2, MATE1 and 
MATE2-K are involved in the renal handling of cationic drugs.   
The mechanism behind the cellular uptake of cisplatin has been investigated in renal 
epithelial cells.  Previous reports showed that the expression of OCT2 enhanced markedly 
the cellular uptake of cisplatin [12-14].  Recently, it was reported that the cumulative urinary 
excretion and nephrotoxicity of cisplatin were reduced in Oct1/2 double-knockout mice [15].  
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In addition, the coadministration of OCT substrates, imatinib and cimetidine, suppressed the 
nephrotoxicity [16, 17].  Based on these reports, uptake via OCT2 is a determinant of the 
nephrotoxicity induced by cisplatin.  The substrate specificities of OCT2 and MATEs are 
similar [18-20].  Therefore, MATEs could also transport cisplatin and affect its 
nephrotoxicity.  However, the role of efflux transporters in the nephrotoxicity of cisplatin is 
still unclear.   
In the present study, we investigated the involvement of MATE1 in the renal 
accumulation and nephrotoxicity of cisplatin by using Mate1(-/-) mice and a specific MATE 
inhibitor, pyrimethamine [21].  In addition, the uptake of cisplatin by mOCT1, mOCT2 and 
mMATE1 was also examined in an in vitro expression system.  
 
 
2. Materials and Methods 
2.1. Animals 
Mate1(-/-) mice were generated previously [11].  All mice used in the experiments were 
wild-type (Mate1(+/+)) or Mate1 (-/-) males with the same genetic background (C57BL/6) 
between 11 and 15 weeks of age.  The animals were fed normal pellet food ad libitum, and 
given water freely.  The animal experiments were conducted in accordance with the 
“Guidelines for Animal Experiments of Kyoto University.”  All protocols were approved by 
the Animal Research Committee, Graduate School of Medicine, Kyoto University.   
 
2.2. Nephrotoxicity and hepatotoxicity of cisplatin 
Mice were administered intraperitoneally cisplatin (15 mg/kg) (Randa®; Nippon Kayaku 
Co., Ltd., Tokyo, Japan).  Pyrimethamine (0.5 mg/kg) (MP Biomedicals, Solon, OH) was 
also injected intraperitoneally 1 h before the administration of cisplatin.  Control mice were 
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administered the equivalent volume of saline.  Two days after the administration of cisplatin, 
mice were maintained in metabolic cages for 24 h to determine the urinary levels of creatinine.  
Blood and urine samples were collected at the end of this period.  For the measurement of 
creatinine, blood urea nitrogen (BUN), aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) levels, we used commercial kits (Wako Pure Chemical Industries, 
Osaka, Japan).   
 
2.3. Renal and hepatic accumulation of cisplatin 
Cisplatin (0.5 mg/kg) was administered as a bolus via the catheterized right femoral vein 
under pentobarbital anesthesia.  Blood was sampled from the abdominal aorta 1 h after the 
administration.  The kidney and liver were then immediately collected, gently washed, 
weighed and homogenized in 9 volumes of saline.  Amounts of platinum were measured 
using inductively coupled plasma-mass spectrometry (ICP-MS) by the Pharmacokinetics and 
Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd. (Wakayama, Japan).   
 
2.4. Cell culture and transfection 
Human embryonic kidney (HEK) 293 cells (American Type Culture Collection 
CRL-1573) were cultured in a complete medium consisting of Dulbecco’s modified Eagle’s 
medium (Wako) with 10% fetal bovine serum (Life Technologies, Carlsbad, CA) in an 
atmosphere of 5% CO2-95% air at 37°C.   
As a transient expression system, pcDNA3.1(+) plasmid vector DNA (Life Technologies) 
or pFLAG-CMV-6b plasmid vector DNA (Sigma-Aldrich, St. Louis, MO), containing 
mOCT1, mOCT2, or mMATE1 cDNA, was purified using a HiSpeed Plasmid Maxi Kit 
(QIAGEN, Hilden, Germany).  The day before transfection, HEK293 cells were seeded onto 
poly-D-lysine-coated 24-well plates at a density of 2.0 x 105 cells per well.  The cells were 
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transfected with 800 ng of DNA using 2 µl of Lipofectamine 2000 (Life Technologies) per 
well according to the manufacturer’s instructions.  Forty-eight hours after the transfection, 
the cells were used for the experiments.   
 
2.5. Uptake experiment 
Uptake experiments were carried out as described previously [22].  Briefly, the 
composition of the incubation buffer was as follows: 145 mM NaCl, 3 mM KCl, 1 mM CaCl2, 
0.5 mM MgCl2, 5 mM D-glucose and 5 mM HEPES (pH 7.4 adjusted with NaOH).  Cells 
expressing mOCT1 or mOCT2 were incubated with the culture medium containing 500 µM 
cisplatin (Sigma-Aldrich) for 1 h.  Cells expressing mMATE1 were incubated with the 
culture medium containing 500 µM cisplatin for 2 min after pre-treatment with 30 mM 
ammonium chloride for 20 min.  After the incubation, the monolayers were rapidly washed 
twice with ice-cold incubation buffer containing 3% BSA (Nacalai Tesque Inc., Kyoto, Japan) 
and then washed three times with ice-cold incubation buffer.  The cells were solubilized in 
0.5 N NaOH, and the amount of platinum was determined using ICP-MS.   
The protein content of the cell monolayers solubilized in 0.5 N NaOH was determined by 
the method of Bradford with a Bio-Rad Protein Assay Kit (Bio-Rad Laboratories, Hercules, 
CA).   
 
2.6. Statistical analysis 
Data were expressed as the mean ± S.D. except mortality data.  A Kaplan-Meier analysis 
and the log rank test were performed to determine the statistical significance of the mortality 
data.  Data were analyzed statistically using the unpaired Student’s t test or multiple 
comparisons with Tukey’s or Dunnett’s two-tailed test after a one-way ANOVA.  Probability 





3.1. Survival of mice treated with cisplatin 
All mice survived at least 3 days after the administration of 15 mg/kg of cisplatin.  
Lifespan was significantly shorter in Mate1(-/-) mice than Mate1(+/+) mice (P=0.02, Fig. 1A).  
Body weights were comparable between the two groups (Fig. 1B).  Plasma creatinine levels 
were significantly higher in Mate1(-/-) mice four days after the administration (Fig. 1C).  In 
the following experiments, renal function was evaluated at Day 3.   
 
3.2. Nephrotoxicity and hepatotoxicity of cisplatin in Mate1(-/-) mice 
Three days after the administration of cisplatin, plasma creatinine, BUN, creatinine 
clearance, AST and ALT levels were examined.  Body weights were reduced by the 
administration of cisplatin in Mate1(+/+) and Mate1(-/-) mice (Fig. 2A).  In Mate(+/+) and 
Mate(-/-) mice, administration of cisplatin significantly increased plasma creatinine and BUN 
levels (Fig. 2B and 2C).  In addition, creatinine clearance was markedly decreased in both 
groups (Fig. 2D).  Moreover, creatinine and BUN levels were significantly elevated in 
cisplatin-treated Mate1(-/-) mice compared to cisplatin-treated Mate1(+/+) mice (Fig. 2B and 
2C).  Creatinine clearance tended to decrease (Fig. 2D).  AST levels were weakly increased 
in Mate1(-/-) mice by the administration of cisplatin, but ALT levels were unchanged (Fig. 2E 
and 2F).   
 
3.3. Renal and hepatic accumulation of cisplatin in Mate1(+/+) and Mate1(-/-) mice 
One hour after the intravenous administration of cisplatin (0.5 mg/kg), the plasma 
concentration, renal accumulation and hepatic accumulation of platinum were compared 
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between Mate1(+/+) and Mate1(-/-) mice.  The plasma concentration and renal accumulation 
were significantly higher in Mate1(-/-) mice (Fig. 3A and 3B), while hepatic accumulation 
was comparable between the groups (Fig. 3C).   
 
3.4. Effect of pyrimethamine on renal function in mice treated with cisplatin 
Recently, it was reported that pyrimethamine was a potent and specific inhibitor of MATE 
[21].  One hour prior to cisplatin administration, pyrimethamine (0.5 mg/kg) was 
administered.  This combination elevated plasma creatinine and BUN levels compared with 
cisplatin alone (Fig. 4A and 4B).   
 
3.5. Uptake of cisplatin by HEK293 cells expressing mOCT1, mOCT2 and mMATE1 
The uptake of platinum was examined in HEK293 cells expressing mOCT1 or mOCT2 
after incubation with 500 µM cisplatin for 1 h.  The accumulation of cisplatin was enhanced 
by mOCT1 and mOCT2 (Fig. 5A).  Furthermore, the cellular accumulation of platinum in 
mMATE1-expressing cells was examined when the cells were treated with 500 µM cisplatin 
for 2 min after pre-treatment with ammonium chloride.  As shown in Fig. 5B, cisplatin was 




Previous studies in vitro and in vivo by ourselves and others have showed 
OCT2-mediated renal accumulation of cisplatin to be a key factor in its nephrotoxicity [12-17, 
22].  However, the molecular mechanism responsible for the efflux of cisplatin from tubular 
cells had not been clarified.  In the present study, the role of MATE1 in the nephrotoxicity of 
cisplatin was examined in vivo.  The nephrotoxicity was potentiated in Mate1(-/-) mice 
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compared with Mate1(+/+) mice (Fig. 2B and 2C).  Moreover, the renal accumulation of 
cisplatin was significantly increased in Mate1(-/-) mice (Fig. 3B), as previously reported for 
other substrates, such as metformin and cephalexin [11, 23].  On the other hand, MATE1 had 
only a minor role in the hepatic accumulation and hepatotoxicity of cisplatin (Figs. 2E, 2F and 
3C).  The present study strongly suggested that MATE1 as well as OCT2 is involved in the 
renal handling of cisplatin, and a determinant of cisplatin-induced nephrotoxicity.   
A congenital deficiency of transporters could affect the intracellular environment, such as 
cellular signalling or metabolic pathways, by altering the cellular accumulation of endogenous 
substrates.  For example, disruption of ATP-binding cassette transporter 8 (ABC8/ABCG1), 
which facilitates cholesterol efflux, induced the expression of inflammation markers, 
cytokines and cytokine receptors including cathepsin B, tumor necrosis factor-α and 
monocyte chemoattractant protein-1, in the lung of mice [24].  There was another report that 
loss of peptide transporter 2 (PEPT2/SLC15A2) reduced the renal concentrations of cysteine 
and glycine, substrates for glutathione synthesis, suggesting that sensitivity to oxidative stress 
was enhanced [25].  In the present study, we used not only Mate1(-/-) mice, but also a potent 
and specific MATE inhibitor, pyrimethamine [21].  The nephrotoxicity of cisplatin was also 
potentiated by the concomitant administration of pyrimethamine (Fig. 4).  These findings 
suggested that not only a congenital deficiency but also a temporary functional deficiency of 
MATE1 could exacerbate the nephrotoxicity of cisplatin.   
The use of an OCT2 inhibitor is one way to prevent the nephrotoxicity of cisplatin.  We 
previously reported that the concomitant administration of imatinib, a OCT substrate, 
prevented cisplatin-induced nephrotoxicity based on competitive inhibition of the 
OCT2-mediated renal accumulation of cisplatin [16].  Another OCT substrate, cimetidine, 
also ameliorated the nephrotoxicity of cisplatin at a high dose [17].  However, the substrate 
specificities of MATE1 and OCT2 are similar [18-20].  OCT substrates could competitively 
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inhibit the transport activity of MATE, depending on their affinity for OCT or MATE and 
blood concentration.  In fact, it was recently reported that cimetidine inhibited hMATE1 
more potently than hOCT2 [20, 26].  In addition, the renal concentrations of several cationic 
drugs were higher than the plasma concentrations [11, 27].  Therefore, cationic drugs would 
potentially inhibit MATEs rather than OCT2.  The MATE1 inhibitor pyrimethamine 
potentiated cisplatin-induced nephrotoxicity (Fig. 4).  For renoprotection using an OCT2 
inhibitor during treatment with cisplatin, the possibility that nephrotoxicity is actually 
potentiated by the inhibition of MATEs when OCT2 inhibition is not complete should be 
considered.   
We previously reported that the cellular uptake of cisplatin for 1 h was increased by the 
expression of hMATE1 and hMATE2-K without pre-treatment with ammonium chloride [14].  
On the other hand, there was no significant stimulation of the intracellular accumulation of 
platinum in hMATE1 and hMATE2-K-expressing cells after incubation with cisplatin for 2 
min under conditions of ammonium chloride-generated intracellular acidification [22].  An 
inhibitory effect of cisplatin on the transport of tetraethylammonium by hMATE1 and 
hMATE2-K was observed [14].  It is still unclear whether cisplatin is a substrate for human 
MATEs.  More importantly, cisplatin is aquated to the active species in the cell in a 
non-enzymatic reaction.  Therefore, it should be also considered whether an active form of 
cisplatin was transported by MATEs.  In the present study, cisplatin was transported by 
mMATE1 as well as mOCT1 and mOCT2 in the uptake experiments (Fig. 5), and the renal 
accumulation of cisplatin was increased in Mate1(-/-) mice (Fig. 3B).  These results 
indicated that cisplatin was exported from renal epithelial cells in mice.  It was previously 
reported that the renal clearance of cisplatin exceeded the glomerular filtration rate in humans 
and rats [28, 29], suggesting that cisplatin was secreted across renal tubular cells.  Therefore, 
the hMATE family would have a role in the efflux of cisplatin from renal epithelial cells.  
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Further study is needed to reveal the contribution of hMATEs to the renal handling of 
cisplatin in humans.   
In conclusion, the present study using Mate1(-/-) mice strongly suggested that MATE1 
mediates the efflux of cisplatin from renal tubular epithelial cells and is involved in 
cisplatin-induced nephrotoxicity.  A genetic deficiency or drug-drug interaction in MATE 
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Legends for figures 
Fig. 1.  Survival rates, body weights and plasma creatinine levels of cisplatin-treated mice.  
(A) Kaplan-Meier survival curve for Mate1(+/+) (solid; n = 6) and Mate1(-/-) (dotted; n = 6) 
mice after the administration of cisplatin (15 mg/kg).  The body weights (B) and plasma 
creatinine levels (C) of Mate1(+/+) (open circles) and Mate1(-/-) mice (closed circles) were 
also examined at Days 1, 2, 4 and 7.  Each point represents the mean ± S.D.  **P<0.01, 
significantly different from Mate1(+/+) mice.   
 
Fig. 2.  Nephrotoxicity and hepatotoxicity of cisplatin in Mate1(+/+) and Mate1(-/-) mice.  
Biochemical parameters (A: Body weight; B: Plasma creatinine; C: BUN; D: Creatinine 
clearance; E: AST; F: ALT) were examined three days after the administration of cisplatin (15 
mg/kg).  Each bar represents the mean ± S.D. for five or six mice from two independent 
experiments.  †P<0.05; ††P<0.01, significantly different from pre-administration.  
*P<0.05; **P<0.01; ***P<0.001, significantly different.   
 
Fig. 3.  Plasma concentration (A), renal accumulation (B) and hepatic accumulation (C) of 
cisplatin in Mate1(+/+) and Mate1(-/-) mice.  The plasma, kidney and liver were collected 1 
h after the administration of cisplatin (0.5 mg/kg), and the kidney and liver were homogenized 
in 9 volumes of saline.  The concentration of platinum in each sample was determined by 
ICP-MS.  Each bar represents the mean ± S.D. for five mice.  *P<0.05; **P<0.01, 
significantly different.   
 
Fig. 4.  Effect of pyrimethamine on renal function in wild-type mice treated with cisplatin.  
Plasma creatinine (A) and BUN (B) levels were examined three days after the administration 
of cisplatin (15 mg/kg) with pyrimethamine (0.5 mg/kg) or cisplatin (15 mg/kg) alone.  Each 
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bar represents the mean ± S.D. for eight or nine mice from two independent experiments.  
*P<0.05; ***P<0.001, significantly different.   
 
Fig. 5.  Uptake of cisplatin by HEK293 cells expressing mOCT1, mOCT2 and mMATE1.  
(A) HEK293 cells were transfected with empty vector (open bar), mOCT1 (gray bar), or 
mOCT2 (black bar).  The cells were treated with medium containing 500 µM cisplatin for 1 
h.  After being washed, the cells were solubilized in 0.5 N NaOH, and the amount of 
platinum was determined by ICP-MS.  (B) HEK293 cells were transfected with empty vector 
(open bar) and mMATE1 (closed bar).  The cells were treated with medium containing 500 
µM cisplatin for 2 min after pretreatment with 30 mM of ammonium chloride for 20 min.  
After being washed, the cells were solubilized in 0.5 N NaOH, and the amount of platinum 
was determined by ICP-MS.  Each bar represents the mean ± S.D. for four wells.  
**P<0.01; ***P<0.001, significantly different from vector-transfected cells.  
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